Top Medicare prescribers rake in speaking fees from drugmakers
When the blood pressure drug Bystolic hit the market in 2008, it faced a crowded field of cheap generics. So its maker, Forest Laboratories, launched a promotional assault on the group in the best position to determine Bystolic's success: those in control of prescription pads. It flooded the offices of health professionals with drug reps, and it hired doctors to persuade their peers to choose Bystolic ? even though the drug hadn't proved more effective than competitors. The strategy worked. In the 2012 fiscal year, sales of Bystolic reached $348 million, almost double its total from two years earlier, the company reported.
- Providers' Push to Consolidate Roils Payers
- As Retail Clinics Surge, Quality Metrics MIA
- Former NQF Co-Chair Linked to Conflicts of Interest in Journal Probe
- RN Named Chief Patient Experience Officer
- Medicare Cost, Quality Data Tools Weak, Says GAO
- No Employee Satisfaction, No Patient-Centered Culture
- In PCMH, the 'P' is Not for 'Physician'
- Population Health Pays Off for NY Collaborative
- Six Not-So-Good Reasons for Avoiding Population Health
- How Simple Data Analytics is Driving Physician Incentives